Item 1. Security and Issuer

This Amendment No. 6 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, as previously amended by Amendments No. 1, No. 2, No. 3, No. 4 and No. 5 to Schedule 13D, with respect to the Common Stock, $0.0001 par value per share (the “Shares”), of Rennova Health, Inc., a Delaware corporation (the “Issuer”), filed by: Seamus Lagan; Alcimede LLC, a Delaware limited liability company (“Alcimede”); Epizon Ltd. (“Epizon”), a Bahamian international business corporation, which is wholly-owned by The Shanoven Trust, of which P. Wilhelm F. Toothe serves as the trustee; P. Wilhelm F. Toothe, as trustee of The Shanoven Trust; and The Shanoven Trust. Except as expressly amended below, Schedule 13D, dated November 2, 2015, as previously amended, remains in effect. The share numbers in this Amendment No. 6 reflect the 1-for-500 reverse split of the Shares effective November 12, 2018.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended to include the following:

This Amendment No. 6 to Schedule 13D is being filed to report the change in the conversion price of the Issuer’s Series J Convertible Preferred Stock (the “Series J Preferred Stock”) owned by Alcimede, and consequently the number of shares into which they are convertible. Alcimede owns all of the outstanding Series J Preferred Stock. Each share of Series J Preferred Stock is convertible, at any time at the option of the holder, into that number of Shares determined by dividing the stated value (which is $1.00 per share) of such share of Series J Preferred Stock, plus any accrued and unpaid dividends thereon, by the conversion price. The conversion price is equal to the average closing price of the Shares on the 10 trading days immediately prior to the conversion date. Since March 18, 2019, the shares of Series J Preferred Stock owned by Alcimede are convertible into 2,500,000,000 Shares.

Each holder of the Series J Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Shares. Each share of Series J Preferred Stock shall be entitled to the whole number of votes equal to the number of Shares into which it is then convertible. The Series J Preferred Stock shall vote with the Shares as if they were a single class of securities.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended to include the following:

As of August 30, 2019, Mr. Lagan may be deemed to beneficially own 2,500,053,384 Shares (or approximately 26.86% of the total number of Shares then currently deemed outstanding), which consists of 53,360 Shares owned of record by Mr. Lagan and 16 stock options owned of record by Mr. Lagan, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power; and 8 Shares owned of record by Alcimede and 2,500,000,000 Shares into which the Series J Preferred Stock owned of record by Alcimede are convertible as of August 30, 2019. Mr. Lagan may be deemed to have shared dispositive and voting power with Alcimede over the 8 Shares owned of record by Alcimede and the 2,500,000,000 Shares into which the Series J Preferred Stock owned of record by Alcimede are convertible as of August 30, 2019. Because the conversion price of the Series J Preferred Stock is determined by the average closing price of the Shares for the 10 trading days immediately prior to the conversion date, the number of Shares issuable upon conversion will increase or decrease depending upon the market price of the Shares at any particular time. Such Shares do not include 17 Shares owned of record by Epizon and with respect to such Shares, The Shanoven Trust, P. Wilhelm F. Toothe, as trustee of The Shanoven Trust, and Epizon share dispositive and voting power. Such Shares also do not include Shares owned by a third party entity, and which third party entity is owned by a trust of which P. Wilhelm F. Toothe serves as trustee.

Item 7. Materials to be Filed as Exhibits

Item 7 is hereby amended to include the following:

Exhibit D – Joint Filing Agreement pursuant to Rule 13d-1(k).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Exhibit D

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Amendment No.6 to Schedule 13D is filed on behalf of each of the undersigned. The undersigned acknowledge that each shall be responsible for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent it knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any number of counterparts and all of such counterparts taken together shall constitute one and the same instrument.

Dated: October 24, 2019